INmune Bio Soars 10.68% Awaiting FDA Decision

INmune Bio's stock surged 10.68% in pre-market trading on May 20, 2025, marking a significant rise for the biotech company.

INmune Bio is currently facing a pivotal moment with the upcoming FDA decision on its Phase 2 trial results for XPro, a treatment for Alzheimer's disease. This decision, expected in May 2025, could have a substantial impact on the company's future trajectory and investor sentiment.

The biotech sector is closely monitoring key readouts and FDA decision dates, as these events often drive market trends and stock performance. INmune Bio's upcoming results are among the most anticipated in the industry, given the potential of XPro to address a significant unmet medical need.